Bioatla Inc
bioatla.comWhat Do They Do?
Develops antibody-based drug candidates for solid tumors, including antibody-drug conjugates and bispecific antibodies, for cancer patients.
10-K for FY2025, filed Mar 31, 2026
Who Are Their Customers?
Works with partner companies through licensing and research arrangements; Context licensed BA3362 and funds supplementary preclinical research.
10-K for FY2025, filed Mar 31, 2026We have entered into collaborations and licensing agreements with various third parties that, in some cases, may provide for potential…View ↗
Do Revenues Turn Into Profits?
No. It lost $59.6M in FY2025.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
$452KView ↗
- ▲ Now profitable
- vs −$18.7M in Q2 FY2025
-
Aug 28, 2026
Nasdaq affirmed its decision to delist BioAtla's common stock
Nasdaq trading is scheduled to be suspended unless its board calls the decision for review.
Sources
8-K, filed Aug 28, 2026
On August 26, 2026, the Listing Council notified the Company that it had issued a decision affirming the prior determination of the Panel…View ↗
Loading...
